利福昔明在肝硬化患者中的应用
本文综述利福昔明(一种口服非系统性抗生素)在肝硬化患者中的潜在作用机制与临床疗效。利福昔明预防肝性脑病(HE)复发已获大型随机临床试验证实,但对其他并发症如自发性细菌性腹膜炎的防治证据尚弱;其通过调节肠道微生物组影响肠-肝轴,可能干预肝硬化失代偿的病理生理 cascade,但需双盲、足够把握度的随机临床试验评估对失代偿、慢加急性肝衰竭和死亡率等硬终点的效果。
要点
- 利福昔明预防HE复发有效且安全,已获大型随机临床试验证实。
- 对自发性细菌性腹膜炎等其他细菌感染的防治证据弱,尚不被接受。
- 利福昔明可能通过调节肠道微生物组影响肠-肝轴,干预肝硬化失代偿机制。
核心结论
- 利福昔明预防HE复发的疗效和安全性已获大型随机临床试验证实,但对其他并发症的防治证据仍弱,需进一步研究。
研究设计与样本
- 本文为综述,检索范围未在摘要中明确报告。
主要发现
- 利福昔明是一种口服非系统性抗生素,胃肠道吸收极少,抗菌谱广,覆盖革兰阳性和革兰阴性菌。
- 近十年实验和临床证据提示利福昔明可能通过调节肠道微生物组和影响肠-肝轴,对肝硬化病程产生其他有益效应。
- 利福昔明可能干扰失代偿肝硬化病理生理 cascade 中的主要事件,如全身炎症综合征、门静脉高压和细菌感染。
- 利福昔明用于预防或治疗自发性细菌性腹膜炎或其他细菌感染尚不被接受,因临床试验证据仍很弱。
关键数值与推荐
- 利福昔明当前全球用于肝硬化患者预防HE复发,基于大型随机临床试验证实的疗效和安全性。
- 利福昔明对自发性细菌性腹膜炎或其他细菌感染的防治不被接受,因临床试验证据仍很弱。
临床怎么用
- 利福昔明可用于肝硬化患者预防HE复发。
- 不推荐利福昔明用于预防或治疗自发性细菌性腹膜炎或其他细菌感染,因证据不足。
- 利福昔明对其他并发症的潜在益处需等待双盲、足够把握度的随机临床试验结果。
局限性
- 利福昔明对HE以外并发症的防治证据仍很弱。
- 评估利福昔明对硬临床终点(如肝硬化失代偿、慢加急性肝衰竭和死亡率)效果的双盲、足够把握度的随机临床试验结果尚待公布。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and broad-spectrum antibacterial activity covering both gram-positive and gram-negative organisms. Rifaximin is currently used worldwide in patients with cirrhosis for preventing recurrent HE because its efficacy and safety have been proven by large randomized clinical trials. In the last decade, experimental and clinical evidence suggest that rifaximin could have other beneficial effects on the course of cirrhosis by modulating the gut microbiome and affecting the gut-liver axis, which in turn can interfere with major events of the pathophysiological cascade underlying decompensated cirrhosis, such as systemic inflammatory syndrome, portal hypertension, and bacterial infections. However, the use of rifaximin for prevention or treatment of other complications, including spontaneous bacterial peritonitis or other bacterial infections, is not accepted because evidence by clinical trials is still very weak. The present review deals in the first part with the potential impact of rifaximin on pathogenic mechanisms in liver diseases, whereas in the second part, its clinical effects are critically discussed. It clearly emerges that, because of its potential activity on multiple pathogenic events, the efficacy of rifaximin in the prevention or management of complications other than HE deserves to be investigated extensively. The results of double-blinded, adequately powered randomized clinical trials assessing the effect of rifaximin, alone or in combination with other drugs, on hard clinical endpoints, such as decompensation of cirrhosis, acute-on-chronic liver failure, and mortality, are therefore eagerly awaited.
引用
- Caraceni P, Vargas V, Solà E, et al. The Use of Rifaximin in Patients With Cirrhosis. Hepatology. 2021. PMID: 33421158. doi:10.1002/hep.31708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。